Онкогематология (Nov 2022)
Minimal residual disease prognostic value for relapse-free survival of children with acute lymphoblastic leukemia treating according to ALL-MB-2002 protocol (monofactorial and multifactirial analysis)
Abstract
220 children with acute lymphoblastic leukemia (ALL) treated according to ALL-MB-2002 protocol are included in the study. Minimal residual disease (MRD) estimated in bone marrow by three-color flow cytometry on day 15 (n=99), day 36 (n=107) and before the maintenance therapy (n=60). Day 36 positive MRD level (≥0.01%) as one of unfavorable factors statistically significant worsening of relapse-free survival was revealed (log-rank test; р<0.05). In multifactorial analysis (Cox regression) it is revealed that positive MRD level on day 36 of treatment is the strongest and independent prognostic factor influencing relapse probability (hazard ratio 6.6; p=0.031). Necessity of additional patients' stratification introduction according to MRD level after induction is proved.
Keywords